Targeted Therapy Targeted Therapies Clinical Trials Cancer Treatment Target Identification Neurotherapeutics Alzheimer's Treatments Molecular Targets Gene Therapy Weight Loss Drugs Genetic Targets Senolytics NRP1 Inhibitors Novel Therapies GSK3-beta Inhibition cGAS-STING Pathway Disease-Modifying Therapies Neurodegenerative Diseases RNA-targeted Therapies Protein Targeting Protein Therapy Appetite Suppressants Obesity Treatments Immunotherapy FDA Approval Microbiome Considerations Diabetes Treatment Hormonal Therapies Prophylactic Treatments Biologics Metabolic Therapies Mitochondrial Dysfunction Ferroptosis Neurological Treatments Neuroscience Applications Anti-obesity Treatments Therapeutic Strategies Preventive Medicine Innovative Therapies Target Engagement NAD+ Augmentation Inflammation Antioxidants Atherosclerosis Treatment Repurposed Drugs ACLY Inhibitors Preclinical Research Mitochondrial-targeted Therapies Metabolic Disorders Lithium Treatments Clinical Trial Efficiency Anti-fibrotic Drugs Side Effects Anti-inflammatory Drugs Cancer Treatments Sleep Medications Hypoxia Treatments Oligonucleotide Therapy Protein Modulation Compound Screening GPCR Targeting Neuroprotective Agents Antivenoms G Protein-Coupled Receptors CAMKK2 Inhibitors MAOB Inhibitors Psychedelic Research Immune Modulation Cell Movement Manipulation
The preclinical findings point to a vessel‑focused approach that could reduce side effects compared with blocking the body‑wide PI3K pathway.
